FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095562317> ?p ?o ?g. }

• W3095562317 endingPage "e1003229" @default.
• W3095562317 startingPage "e1003229" @default.
• W3095562317 abstract "Background Higher maternal plasma glucose (PG) concentrations, even below gestational diabetes mellitus (GDM) thresholds, are associated with adverse offspring outcomes, with DNA methylation proposed as a mediating mechanism. Here, we examined the relationships between maternal dysglycaemia at 24 to 28 weeks’ gestation and DNA methylation in neonates and whether a dietary and physical activity intervention in pregnant women with obesity modified the methylation signatures associated with maternal dysglycaemia. Methods and findings We investigated 557 women, recruited between 2009 and 2014 from the UK Pregnancies Better Eating and Activity Trial (UPBEAT), a randomised controlled trial (RCT), of a lifestyle intervention (low glycaemic index (GI) diet plus physical activity) in pregnant women with obesity (294 contol, 263 intervention). Between 27 and 28 weeks of pregnancy, participants had an oral glucose (75 g) tolerance test (OGTT), and GDM diagnosis was based on diagnostic criteria recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG), with 159 women having a diagnosis of GDM. Cord blood DNA samples from the infants were interrogated for genome-wide DNA methylation levels using the Infinium Human MethylationEPIC BeadChip array. Robust regression was carried out, adjusting for maternal age, smoking, parity, ethnicity, neonate sex, and predicted cell-type composition. Maternal GDM, fasting glucose, 1-h, and 2-h glucose concentrations following an OGTT were associated with 242, 1, 592, and 17 differentially methylated cytosine-phosphate-guanine (dmCpG) sites (false discovery rate (FDR) ≤ 0.05), respectively, in the infant’s cord blood DNA. The most significantly GDM-associated CpG was cg03566881 located within the leucine-rich repeat-containing G-protein coupled receptor 6 (LGR6) (FDR = 0.0002). Moreover, we show that the GDM and 1-h glucose-associated methylation signatures in the cord blood of the infant appeared to be attenuated by the dietary and physical activity intervention during pregnancy; in the intervention arm, there were no GDM and two 1-h glucose-associated dmCpGs, whereas in the standard care arm, there were 41 GDM and 160 1-h glucose-associated dmCpGs. A total of 87% of the GDM and 77% of the 1-h glucose-associated dmCpGs had smaller effect sizes in the intervention compared to the standard care arm; the adjusted r 2 for the association of LGR6 cg03566881 with GDM was 0.317 (95% confidence interval (CI) 0.012, 0.022) in the standard care and 0.240 (95% CI 0.001, 0.015) in the intervention arm. Limitations included measurement of DNA methylation in cord blood, where the functional significance of such changes are unclear, and because of the strong collinearity between treatment modality and severity of hyperglycaemia, we cannot exclude that treatment-related differences are potential confounders. Conclusions Maternal dysglycaemia was associated with significant changes in the epigenome of the infants. Moreover, we found that the epigenetic impact of a dysglycaemic prenatal maternal environment appeared to be modified by a lifestyle intervention in pregnancy. Further research will be needed to investigate possible medical implications of the findings. Trial registration ISRCTN89971375 ." @default.
• W3095562317 created "2020-11-09" @default.
• W3095562317 creator A5000938397 @default.
• W3095562317 creator A5021605951 @default.
• W3095562317 creator A5023389666 @default.
• W3095562317 creator A5030546346 @default.
• W3095562317 creator A5031184713 @default.
• W3095562317 creator A5032448943 @default.
• W3095562317 creator A5045203195 @default.
• W3095562317 creator A5045412197 @default.
• W3095562317 creator A5055704111 @default.
• W3095562317 creator A5063502440 @default.
• W3095562317 creator A5066683443 @default.
• W3095562317 creator A5068954497 @default.
• W3095562317 creator A5073241743 @default.
• W3095562317 creator A5073767847 @default.
• W3095562317 creator A5085200750 @default.
• W3095562317 creator A5086946399 @default.
• W3095562317 creator A5091772545 @default.
• W3095562317 date "2020-11-05" @default.
• W3095562317 modified "2023-10-17" @default.
• W3095562317 title "Maternal dysglycaemia, changes in the infant’s epigenome modified with a diet and physical activity intervention in pregnancy: Secondary analysis of a randomised control trial" @default.
• W3095562317 cites W1845326899 @default.
• W3095562317 cites W1863728472 @default.
• W3095562317 cites W1969792452 @default.
• W3095562317 cites W2009961905 @default.
• W3095562317 cites W2015364707 @default.
• W3095562317 cites W2049624032 @default.
• W3095562317 cites W2065020285 @default.
• W3095562317 cites W2071727585 @default.
• W3095562317 cites W2097610667 @default.
• W3095562317 cites W2099176456 @default.
• W3095562317 cites W2101870168 @default.
• W3095562317 cites W2104476055 @default.
• W3095562317 cites W2104549677 @default.
• W3095562317 cites W2106014075 @default.
• W3095562317 cites W2107665951 @default.
• W3095562317 cites W2114819974 @default.
• W3095562317 cites W2115371848 @default.
• W3095562317 cites W2117367121 @default.
• W3095562317 cites W2118063646 @default.
• W3095562317 cites W2121328463 @default.
• W3095562317 cites W2125767272 @default.
• W3095562317 cites W2131998216 @default.
• W3095562317 cites W2133246071 @default.
• W3095562317 cites W2134478413 @default.
• W3095562317 cites W2143243643 @default.
• W3095562317 cites W2143858605 @default.
• W3095562317 cites W2146512944 @default.
• W3095562317 cites W2148462747 @default.
• W3095562317 cites W2150727212 @default.
• W3095562317 cites W2154688683 @default.
• W3095562317 cites W2164404896 @default.
• W3095562317 cites W2166039665 @default.
• W3095562317 cites W2169556367 @default.
• W3095562317 cites W2171030481 @default.
• W3095562317 cites W2171452751 @default.
• W3095562317 cites W2180709391 @default.
• W3095562317 cites W2255104527 @default.
• W3095562317 cites W2324966680 @default.
• W3095562317 cites W2337476538 @default.
• W3095562317 cites W2463708289 @default.
• W3095562317 cites W2475941856 @default.
• W3095562317 cites W2500601517 @default.
• W3095562317 cites W2511515754 @default.
• W3095562317 cites W2516373504 @default.
• W3095562317 cites W2529024004 @default.
• W3095562317 cites W2563835520 @default.
• W3095562317 cites W2590902394 @default.
• W3095562317 cites W2596677497 @default.
• W3095562317 cites W2598807087 @default.
• W3095562317 cites W2600840322 @default.
• W3095562317 cites W2605491015 @default.
• W3095562317 cites W2616235706 @default.
• W3095562317 cites W2725077761 @default.
• W3095562317 cites W2761687633 @default.
• W3095562317 cites W2762255589 @default.
• W3095562317 cites W2792118266 @default.
• W3095562317 cites W2794584941 @default.
• W3095562317 cites W2795985395 @default.
• W3095562317 cites W2802494678 @default.
• W3095562317 cites W2889958681 @default.
• W3095562317 cites W2897910616 @default.
• W3095562317 cites W2899423833 @default.
• W3095562317 cites W2906058661 @default.
• W3095562317 cites W2908159319 @default.
• W3095562317 cites W2908588538 @default.
• W3095562317 cites W2910413249 @default.
• W3095562317 cites W2911007152 @default.
• W3095562317 cites W2950541136 @default.
• W3095562317 cites W2970782252 @default.
• W3095562317 cites W2979921170 @default.
• W3095562317 doi "https://doi.org/10.1371/journal.pmed.1003229" @default.
• W3095562317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7643947" @default.
• W3095562317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33151971" @default.
• W3095562317 hasPublicationYear "2020" @default.
• W3095562317 type Work @default.
• W3095562317 sameAs 3095562317 @default.

• next